Scleroderma and chronic myeloid leukemia: A sheer coincidence, a consequence of long lasting D-penicillamine therapy or a plausible relationship of both diseases?

Rheumatology International

Volumn 27, Issue 2, 2006, Pages 175-177

  Kaşifoǧlu, Timuçin ^a   Korkmaz, Cengiz ^a   Yaşar, Şule ^a   Gülbaş, Zafer ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Chronic myeloid leukemia; CREST; Scleroderma

Indexed keywords

HYDROXYUREA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE;

ADD ON THERAPY; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; PHYSICAL EXAMINATION; POLYARTHRITIS; PRIORITY JOURNAL; REMISSION; SCLERODERMA; SYNDROME CREST;

ANTIRHEUMATIC AGENTS; CREST SYNDROME; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PENICILLAMINE;

EID: 33846176558     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0167-7     Document Type: Article

References (19)

1. Wooten MD, Scott JW, Miller AM, Boh E (1998) Chronic myelogenous leukemia and porphyria cutanea tarda in a patient with limited systemic sclerosis. South Med J 91:493-495
2. Grove ML, Hassell AB, Hay EM, Shadforth MF (2001) Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 94:309-319
3. Gilman PA, Holtzman NA (1982) Acute lymphoblastic leukemia in a patient receiving penicillamine for Wilson's disease. JAMA 248:467-468
4. Clausen JE, Arndal JC, Gram L, Kudahl SB (1978) Chronic lymphocytic leukaemia after treatment with penicillamine. Lancet 2(8081):152
5. Nakanishi H, Takehara K, Soma Y, Ishibashi Y (1989) Atypical scleroderma associated with multiple myeloma. Dermatologica 178:176-178
6. Sidi Y, Fadilah R, Pinkhas J, Prokocimer M (1990) Systemic sclerosis and chronic lymphocytic leukaemia. Postgrad Med J 66:1071-1072
7. Duggal L, Gupta S, Aggarwal PK, Sachar VP, Bhalla S (2002) Hodgkin's disease and scleroderma. J Assoc Physicians India 50:1186-1188
8. Pulik M, Teillet-Thiebaud F, Mahe A, Teillet F (1991) Non-Hodgkin's lymphoma associated with scleroderma. Presse Med 20:1513-1514
9. Cavallero GB, Bonferroni M, Gallamini A, Grasso M, Carbone A (1994) Scleroderma and hairy-cell leukemia. Eur J Haematol 52:189-190
10. Roumm AD, Medsger TA Jr (1985) Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum 28:1336-1340
11. Watanabe S, Sugihara T, Takahashi M, et al (1994) Concordant improvement of progressive systemic sclerosis and chronic myelogenous leukemia with interferon-alpha treatment. Rinsho Ketsueki 35:895-897
12. Emerit I, Levy A, Housset E (1973) Generalized scleroderma and chromosome breakage. Demonstration of a breaking factor in patients serum. Ann Genet 16:135-138
13. Rittner G, Schwanitz G, Baur MP, et al (1988) Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet 81:64-70
14. Pan SF, Rodnan GP, Deutsch M, Wald N (1975) Chromosomal abnormalities in progressive systemic sclerosis (scleroderma) with consideration of radiation effects. J Lab Clin Med 86:300-308
15. Kurbegov D, Molldrem JJ (2004) Immunity to chronic myelogenous leukemia. Hematol Oncol Clin N Am 18:733-752
16. Riccieri V, Parisi G, Spadaro A, et al (2005) Reduced circulating natural killer T cells and γ/T cells in patients with systemic sclerosis. J Rheumatol 32:283-286
17. Seaman WE (2000) Natural killer cells and natural killer T cells. Arthritis Rheum 43:1204-1217
18. Stevens W, Vancheeswaran R, Black CM (1992) Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study: UK systemic sclerosis study group. Br J Rheumatol 31:683-689
19. Bonifazi F, de Vivo A, Rosti G, et al (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074-3081